Domainex invests in the Creoptix WAVEdelta to strengthen its fragment-based drug discovery platform
Wädenswil/Zurich, Switzerland and Saffron Walden, UK, 12th January 2021 / Sciad Newswire / Domainex Ltd., a leading provider of integrated drug discovery services, is pleased to announce that it has invested in the WAVEdelta instrument from Creoptix AG. This instrument utilizes Grating-Coupled Interferometry (GCI) to measure target binding on sensor chips, generating binding affinity and on/off rate kinetics in a high throughput manner. This system achieves superior resolution in signal and time compared to traditional Surface Plasmon Resonance (SPR) and will further strengthen Domainex’s leading position in the fragment-based drug discovery field via its FragmentBuilder platform.
Under the terms of the agreement, Creoptix has delivered its latest pre-launch WAVEdelta system with its new waveRAPID® (Repeated Analyte Pulses of Increasing Duration) capability built in, to be officially launched in February 2021. This will increase the throughput dramatically and reduce compound consumption by using timed pulsed injections. Simultaneously, Domainex has been appointed to the Creoptix Partnering Program under which Creoptix will refer “fee-for-service” enquiries to Domainex.
Dr. Tom Mander, Chief Executive Officer at Domainex, said: “I have been impressed with the technical expertise and access the team at Creoptix have given us, under Line’s stewardship. We are pleased to have become one of only three companies to join their Partnering Program. The WAVEdelta system will complement our already comprehensive and world-leading biophysical screening platform. Alongside this, we have recruited more talented scientists with prior experience to cater to the growing demand for such services. Now more than ever, Domainex is positioned as the partner of choice to life science organisations globally for prosecuting challenging disease targets through drug discovery”.
Line Stigen Raquet, Chief Executive Officer of Creoptix, added: “We are very pleased to embark on our partnership with Domainex and grant them early access to our waveRAPID technology as part of our Partnering Program. Domainex and Creoptix share a strong commitment to our customers and helping them achieve scientific breakthroughs, and we are delighted to join forces in the pursuit of this goal”.
For more information, contact:
Dr. Tom Mander
Media Relations – Domainex
Deborah Cockerill / Juliette Craggs / Katie Warren
Tel.: +44 (0)20 3405 7892
Notes to editors
About Creoptix AG
Creoptix is a private company headquartered in Wädenswil, near Zurich, Switzerland, and with US offices in the Boston area. Creoptix focuses on next-generation bioanalytical instruments for drug discovery and life sciences for both industry and academic research. Based on its proprietary sensor and microfluidics technology, the Creoptix WAVEsystem provides exceptionally high sensitivity and resolution to study real-time biological interactions involving small molecules, peptides, membrane proteins, biologics, and other molecules even in biofluids like undiluted serum or plasma. Find more information at www.creoptix.com
About Domainex Ltd.
Domainex is a leading integrated medicines research service partner working with ambitious life science organisations from around the globe. We have been setting new standards in research since 2001, working collaboratively with pharmaceutical and biotechnology companies, patient foundations and leading academic institutions.
We provide innovative and customised assay and structural biology and computational, synthetic, medicinal and analytical chemistry services to advance the disease research projects of our partners, from target expression to pre-clinical development candidate nomination. Working with Domainex maximises the chance of successful progression for our partners’ research and our approach consistently saves up to 30% of the time needed to discover new medicines by comparison with the industry average. Our innovative science and extensive technical capabilities enable us to produce novel medicines to treat diseases with strong commercial potential. We work closely and collaboratively with our customers to understand their aspirations, bringing our ideas, know-how and wealth of experience to bear on their projects.
Our highly qualified and experienced team of dedicated research scientists has an unrivalled breadth of knowledge, access to a wide range of technologies and a proven track record of successful innovation in solving research challenges including being named on over 60 patent applications and the invention of numerous candidate drugs. We aim to deliver successful outcomes efficiently and quickly, setting the highest possible benchmark in medicines research.
Full information about Domainex and our award-winning services can be found at www.domainex.co.uk.